Oncology On The Go

S1 Ep181: Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC


Listen Later

In a conversation with CancerNetwork® following the FDA approval of the gemcitabine intravesical system (Inlexzo; formerly TAR-200) for patients with high-risk, Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC), Gary Steinberg, MD, discussed how this regulatory decision may impact the treatment paradigm.

Steinberg, a professor in the Department of Urology at Rush University, highlighted an unmet need for those with BCG-unresponsive, high-grade NMIBC. With a different mechanism of action compared with prior therapeutic choices in the field, he stated that the gemcitabine intravesical system may allow patients and physicians to benefit tremendously. Based on supporting data from the phase 2 SunRISe-1 trial (NCT04640623), he described how the gemcitabine intravesical system may replace prior standards such as intravesical gemcitabine plus docetaxel.

The conversation also touched upon considerations for preventing the risk of progression to metastatic disease with delayed cystectomy, as Steinberg emphasized following up with patients via cystoscopies, urinary cytologies, CT scans, or MRI imaging after treatment with the intravesical system. Steinberg also detailed strategies for mitigating urinary frequency, dysuria, and other toxicities associated with the therapy. He noted a “fine line” regarding bladder medication administration to older patient populations, as these practices may cause adverse effects such as dry mouth, constipation, and blurry vision.

Looking ahead, Steinberg illustrated a need to clarify the immunologic effects of regimens like the gemcitabine intravesical system, which can inform the use of additional therapeutic combinations down the road. He highlighted how other novel agents like cretostimogene grenadenorepvec (CG0070) may further improve outcomes in the NMIBC landscape.

“One of the key questions that we all need to ask with all our treatments is not about the patients who respond, but about the patients who do not respond,” Steingerg stated regarding the potential next steps for research. “We can begin to understand mechanisms of resistance so that we can target those mechanisms of resistance and treat them better.”

Reference

U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to transform how certain bladder cancers are treated. News release. Johnson & Johnson. September 9, 2025. Accessed September 22, 2025. https://tinyurl.com/4zjz22z7

...more
View all episodesView all episodes
Download on the App Store

Oncology On The GoBy CancerNetwork

  • 3.5
  • 3.5
  • 3.5
  • 3.5
  • 3.5

3.5

4 ratings


More shows like Oncology On The Go

View all
Journal of Clinical Oncology (JCO) Podcast by American Society of Clinical Oncology (ASCO)

Journal of Clinical Oncology (JCO) Podcast

39 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

500 Listeners

ASCO Daily News by American Society of Clinical Oncology (ASCO)

ASCO Daily News

58 Listeners

The Daily by The New York Times

The Daily

112,491 Listeners

OncoPharm by John Bossaer

OncoPharm

184 Listeners

The Intelligence from The Economist by The Economist

The Intelligence from The Economist

2,526 Listeners

The Uromigos by The Uromigos

The Uromigos

55 Listeners

The Oncology Podcast by The Oncology Network

The Oncology Podcast

4 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

32 Listeners

Huberman Lab by Scicomm Media

Huberman Lab

29,357 Listeners

The Ezra Klein Show by New York Times Opinion

The Ezra Klein Show

16,009 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

19 Listeners

The Weekly Show with Jon Stewart by Comedy Central

The Weekly Show with Jon Stewart

10,753 Listeners

Two Onc Docs by Sam and Karine

Two Onc Docs

184 Listeners

Oncology Brothers: Practice-Changing Cancer Discussions by Oncology Brothers

Oncology Brothers: Practice-Changing Cancer Discussions

41 Listeners